M. J. Biopharm Private Limited — Insulin Exporter Profile
Indian Pharmaceutical Exporter · #2 for Insulin · $18.9M export value · DGFT Verified
M. J. Biopharm Private Limited is the #2 Indian exporter of Insulin with $18.9M in export value and 303 verified shipments. M. J. Biopharm Private Limited holds a 19.9% market share in Insulin exports across 23 countries. The company exports 6 pharmaceutical products worth $22.4M across 4 therapeutic categories.
M. J. Biopharm Private Limited — Insulin Export Profile: Buyers & Destinations
Where Does M. J. Biopharm Private Limited Export Insulin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| THAILAND | $3.6M | 109 | 43.8% |
| DOMINICAN REPULIC | $911.5K | 24 | 11.2% |
| GUYANA | $802.4K | 25 | 9.9% |
| DOMINICAN REPUBLIC | $439.9K | 13 | 5.4% |
| ETHIOPIA | $388.0K | 9 | 4.8% |
| ZAMBIA | $362.8K | 18 | 4.5% |
| PHILIPPINES | $324.2K | 9 | 4.0% |
| SOUTH AFRICA | $243.2K | 13 | 3.0% |
| MAURITIUS | $200.0K | 4 | 2.5% |
| JAMAICA | $177.8K | 6 | 2.2% |
M. J. Biopharm Private Limited exports Insulin to 24 countries. The largest destination is THAILAND accounting for 43.8% of M. J. Biopharm Private Limited's Insulin shipments, followed by DOMINICAN REPULIC (11.2%) and GUYANA (9.9%). These destinations reflect M. J. Biopharm Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Insulin from M. J. Biopharm Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| BJC HEALTHCARE COMPANY LIMITED | THAILAND | $3.0M | 95 |
| DIABETIKA SRL | DOMINICAN REPULIC | $1.1M | 31 |
| NEW GPC INC | GUYANA | $619.1K | 17 |
| COMMERCIAL BANK OF ETHIOPIA | ETHIOPIA | $388.0K | 9 |
| INTERNATIONAL DRUG COMPANY LIMITED | ZAMBIA | $353.0K | 16 |
| BJC HEALTHCARE CO., LTD. | THAILAND | $300.5K | 7 |
| SIDPHARMA | DOMINICAN REPULIC | $215.2K | 6 |
| NATIONAL HEALTH FUND | JAMAICA | $177.8K | 6 |
| ZUMA PHARMA LLC | UZBEKISTAN | $175.7K | 6 |
| M/S. BJC HEALTHCARE COMPANY LIMITED | THAILAND | $174.2K | 4 |
M. J. Biopharm Private Limited supplies Insulin to 44 buyers globally. The largest buyer is BJC HEALTHCARE COMPANY LIMITED (THAILAND), followed by DIABETIKA SRL (DOMINICAN REPULIC) and NEW GPC INC (GUYANA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Insulin Export Value and How Much Does M. J. Biopharm Private Limited Contribute?
India exported $52.4M worth of Insulin through 2,532 shipments from 188 suppliers to 111 countries, serving 384 buyers globally. M. J. Biopharm Private Limited contributes $18.9M to this total, accounting for 19.9% of India's Insulin exports. M. J. Biopharm Private Limited ships Insulin to 24 countries through 44 buyers.
What Is the Average Shipment Value for M. J. Biopharm Private Limited's Insulin Exports?
M. J. Biopharm Private Limited's average Insulin shipment value is $62.4K per consignment, based on 303 shipments totaling $18.9M. The largest destination is THAILAND (43.8% of M. J. Biopharm Private Limited's Insulin exports).
How Does M. J. Biopharm Private Limited Compare to Other Indian Insulin Exporters?
M. J. Biopharm Private Limited ranks #2 among 188 Indian Insulin exporters with a 19.9% market share. The top 3 exporters are WOCKHARDT LIMITED ($22.7M), M. J. BIOPHARM PRIVATE LIMITED ($15.2M), GLAND PHARMA LTD ($4.0M). M. J. Biopharm Private Limited processed 303 shipments to 23 destination countries.
What Insulin Formulations Does M. J. Biopharm Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| BIOSULIN 3070 INSULIN INJ.BIPHASIC ISOP | $672.5K | 17 |
| BIOSULIN 30:70 INSULIN INJECTION BIPHASI | $516.6K | 13 |
| BIOSULIN N INSULIN INJECTION ISOPHANE PH | $446.9K | 16 |
| BIOSULIN N INSULIN INJ. ISOPHANE PH.EUR. | $142.3K | 3 |
| BIOSULIN 3070 INSULIN INJ.BIPHASIC ISOPHANE PH.EUR.100 IU/ML3ML(HUMAN INSULININJ.100 IU/ML3ML CARTRIDGE)30832 PACKSNOS | $141.5K | 3 |
| BIOSULIN L (INSULIN ZINC INJECTABLE SUSP | $140.6K | 4 |
| BIOSULIN 30/70 INSULIN INJECTION BIPHASIC ISOPHANE PH.EUR.100 IU/ML10 ML (HUMAN INSULIN INJECTION 100 IU/ML10 ML VIALVLS | $138.7K | 3 |
| BIOSULIN N INSULIN INJECTION ISOPHANE PH.EUR.100 IU/ML10 ML (HUMAN INSULIN INJECTION 100 IU/ML10 ML VIALS) 80000PACKSVLS | $127.1K | 3 |
| BIOSULIN 3070 (INSULIN INJ.BIPHASIC ISO | $125.9K | 3 |
| BIOSULIN 30:70 INSULIN INJ.BIPHASIC ISOPHANE PH.EUR.100 IU/ML,3ML(HUMAN INSULIN INJ.100 IU/ML, 3ML CARTRIDGE) | $120.8K | 3 |
M. J. Biopharm Private Limited exports 200 distinct Insulin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is BIOSULIN 3070 INSULIN INJ.BIPHASIC ISOP with 17 shipments worth $672.5K.
How Does M. J. Biopharm Private Limited Compare to Nearest Insulin Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | WOCKHARDT LIMITED | $22.7M | 454 | 25 | $50.0K |
| 2 | M. J. BIOPHARM PRIVATE LIMITED ★ | $15.2M | 303 | 23 | $50.0K |
| 4 | GLAND PHARMA LTD | $4.0M | 81 | 4 | $50.0K |
| 3 | M J BIOPHARM PRIVATE LIMITED ★ | $3.8M | 75 | 15 | $50.0K |
M. J. Biopharm Private Limited ranks #2 among 188 Indian Insulin exporters. Average shipment value of $50.0K compared to the market average of $278.5K. The closest competitors by value are WOCKHARDT LIMITED and GLAND PHARMA LTD.
Which Indian Ports Ship Insulin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 704 | 27.8% |
| SAHAR AIR CARGO ACC (INBOM4) | 646 | 25.5% |
| Bombay Air | 177 | 7.0% |
| Bombay Air Cargo | 123 | 4.9% |
| NHAVA SHEVA SEA (INNSA1) | 108 | 4.3% |
| DELHI AIR | 76 | 3.0% |
| BANGALORE ACC (INBLR4) | 69 | 2.7% |
| JNPT | 68 | 2.7% |
Geopolitical & Trade Policy Impact on M. J. Biopharm Private Limited's Insulin Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like M. J. Biopharm. Escalating tensions in the Middle East, particularly the Israel-Iran conflict, have disrupted key shipping routes through the Red Sea and the Suez Canal. Major carriers have suspended or rerouted shipments, leading to increased transit times and freight costs. This situation poses significant logistical hurdles for time-sensitive pharmaceutical exports. (livemint.com)
Conversely, the U.S.-China trade tensions have prompted the United States to diversify its pharmaceutical supply chain, potentially benefiting Indian exporters. However, the U.S. has also implemented policies favoring domestic manufacturing, such as the "Buy American" initiative, which could impact Indian companies' access to this lucrative market. (walterhealthcare.co.in)
In the European Union, stringent regulations like the Falsified Medicines Directive necessitate rigorous compliance from exporters. Indian companies must navigate these complex requirements to maintain market access, emphasizing the need for robust quality assurance systems. (ipa-india.org)
M. J. Biopharm Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA), World Health Organization (WHO), and European Union Good Manufacturing Practices (EU GMP) set stringent guidelines to ensure product safety and efficacy. Indian companies have faced challenges, including increased compliance costs and potential reductions in export volumes due to evolving regulations. (transdatanexus.com)
For M. J. Biopharm, maintaining adherence to these standards is crucial to sustain and expand its export markets. Investments in quality control, staff training, and infrastructure are essential to meet the evolving requirements and to build trust with international partners and regulatory bodies.
About M. J. Biopharm Private Limited
M. J. Biopharm Private Limited exports 6 products worth $22.4M. Beyond Insulin, top products include Meropenem, Imipenem, Glibenclamide, Ethambutol, Pyrazinamide. View the complete M. J. Biopharm Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Insulin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Insulin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: M. J. Biopharm Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 303 individual customs records matching M. J. Biopharm Private Limited exporting Insulin, covering 200 formulations to 24 countries via 44 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 111+ countries, 384+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Insulin Export Data from M. J. Biopharm Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for M. J. Biopharm Private Limited's Insulin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
M. J. Biopharm Private Limited
Full Company Profile →
6 products · $22.4M total trade · 4 categories
Insulin Stats
Company Overview
Top Products by M. J. Biopharm Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for M. J. Biopharm Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Insulin. For current shipment-level data, contact TransData Nexus.